Evidence map›Paper›PMID 28978155›Full record

ArticleOncotarget2017

A cerebrospinal fluid microRNA signature as biomarker for glioblastoma.

Johnny C Akers, Wei Hua, Hongying Li, Valya Ramakrishnan, Zixiao Yang, Kai Quan, Wei Zhu, Jie Li, Javier Figueroa, Brian R Hirshman and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Johnny C AkersCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Wei HuaDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Hongying LiBiostatistics Department, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
Valya RamakrishnanCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Zixiao YangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Kai QuanDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Wei ZhuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Jie LiCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Javier FigueroaCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Brian R HirshmanCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Brittney MillerCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
David PiccioniDepartment of Neurosurgery, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
Florian RingelDepartment of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Ricardo KomotarDepartment of Neurological Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Karen MesserBiostatistics Department, Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
Douglas R GalaskoDepartment of Neurosciences, University of California, San Diego, CA, USA.
Fred HochbergCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Ying MaoDepartment of Neurosciences, University of California, San Diego, CA, USA.
Bob S CarterCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.
Clark C ChenCenter for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
exRNA Biomarkers for Human GliomaUH3TR000931 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARTER, BOB S, HOCHBERG, FRED H · 2015 to 2017
$3.0M
Targeting Mechanisms of Acquired Temozolomide Resistance in GlioblastomaR01NS097649 · NINDS · UNIVERSITY OF MINNESOTA · PI CHEN, CLARK CHIN-CHUNG · 2016 to 2021
$1.7M
NCATS NIH HHS UH3 TR000931NCI NIH HHS P30 CA023100NIA NIH HHS P50 AG005131NINDS NIH HHS R01 NS097649
6 · The paper itself

Abstract

purposeTo develop a cerebrospinal fluid (CSF) miRNA diagnostic biomarker for glioblastoma. EXPERIMENTAL

designGlioblastoma tissue and matched CSF from the same patient (obtained prior to tumor manipulation) were profiled by TaqMan OpenArray

resultsmiRNA profiles from clinical CSF correlated with those found in glioblastoma tissues. Comparison of CSF miRNA profiles between glioblastoma patients and non-brain tumor patients yielded a tumor "signature" consisting of nine miRNAs. The "signature" correlated with glioblastoma tumor volume (

conclusionWe report a CSF miRNA signature as a "liquid biopsy" diagnostic platform for glioblastoma.

Indexed as

CSFextracellular vesicleliquid biopsy

Identifiers

PMID28978155
PMCPMC5620295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.